Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
343
resultados
Última actualización
03/08/2026 [08:30:00]
Resultados 300 a 325 de 343
Resumen de: WO2026122584A1
Antisense oligonucleotide strategies, including compositions and methods, for increasing protein levels are provided. Target proteins include but are not limited to tank binding protein kinase 1 (TBK-1 or TBK1), follistatin (FST), and progranulin (PGRN). The compositions and methods described herein are applicable for treatment of neurodegenerative diseases caused by haplo-insufficiency.
Resumen de: WO2026120092A1
The present invention relates to methods for the detection and/or quantification of 3-hydroxylated fatty acids (3-OH HFA or 3-hydroxylated HFA) in a sample; in particular a biological sample. The present invention also relates to methods for the detection and/or quantification of lipopolysaccharides (LPS) in a sample. The present invention further relates to such methods, for diagnosing and/or prognosing a disorder in a subject; and/or for monitoring the evolution of a disorder in a subject, or risk thereof; and/or for determining the efficacy of a treatment or prevention of said disorder in a subject in need thereof.
Resumen de: US20260159577A1
0000 The present invention provides polypeptides with the ability to bind selectively to damage-associated molecular patterns (DAMPs), and fusion proteins thereof, for use in treatment of uncontrolled inflammation such as that associated with sepsis. More specifically, the present disclosure is drawn to one such fusion protein, Opsonic Peptide 18 (herein after referred to as “OP18”), and its use as a therapeutic to target and reduce the activity of DAMPs thereby providing treatment of uncontrolled inflammation including that associated with sepsis.
Resumen de: WO2026117869A1
Provided herein are methods for inhibiting lysine uptake or limiting its systemic availability is sufficient to decrease pathogenic catabolite production in cells. These methods useful for reducing the accumulation of pathogenic metabolites in pyridoxine-dependent epilepsy (PDE), glutaric acidemia type I (GA1), hyperlysinemia or other lysine catabolic disorders. In particular, L-lysine oxidase (LOX) enzyme may be systemically administered to reduce the accumulation of lysine and pathogenic metabolites. Furthermore, compounds described herein are absorbed by the skin.
Resumen de: KR20260087123A
0001a 4-tert-octylphenol(4-tert-OP)은 환경에서 널리 발견되는 잠재적으로 유해한 물질입니다. 그럼에도 불구하고 4-tert-OP의 생체 내 독성 동태학에 대한 정보는 부족하고 정량적 위험 평가 연구가 시급히 필요합니다. 따라서 우리는 성별 간 4-tert-OP의 독성 동태학과 조직 내 분포의 차이를 정량적으로 식별하는 것을 목표로 했습니다. 이를 위해 수컷과 암컷 쥐에게 10 또는 50 mg/kg의 4-tert-OP를 경구 투여하고 4 또는 8 mg/kg의 4-tert-OP를 정맥 주사한 후 초고성능 액체 크로마토그래피-탠덤 질량 분석법을 사용하여 샘플에 대한 정량적 분석을 수행했습니다. 결과에 따르면 4-tert-OP 혈장 농도 프로필은 성별 간에 차이가 있었습니다. 그러나 4-tert-OP의 위장관을 통한 전신 흡수는 두 성별 모두 노출 후 0.5시간 이내에 발생했습니다. 비록 적지만 소변과 대변에서 4-tert-OP의 배설 비율은 남성이 여성보다 낮았습니다(노출의 0.06-0.08% 대 0.82-1.11%). 4-tert-OP의 조직 분포 패턴에서도 유의한 성별 차이가 확인되었고 전반적으로 남성의 평균 조직 분포는 여성보다 낮았습니다. 두 성별 모두에서 4-tert-OP의 간, 지방, 비장, 신장, 뇌, 폐 분포가 우세했습니다. 공변량 탐색 모델링 접근법은 성별이 성별 간 4-tert-OP 독성동태학의 차이를 설명한다는 것을 보여주
Resumen de: WO2026118345A1
The present invention provides a rapid, visual, simple, and low-cost immunochromatographic test kit for combined detection of amyloid beta 1-42, NfL, and UCH-L1. The test kit comprises an immunochromatographic test strip, the test strip comprising a sample pad, a conjugate pad, and a nitrocellulose membrane, the conjugate pad comprising microsphere-labeled anti-amyloid beta 1-42, NfL, and UCH-L1 antibody conjugates. Employing combined detection of three markers, amyloid beta 1-42, NfL, and UCH-L1, increases diagnostic accuracy for early detection of Alzheimer's disease and for neurological health.
Resumen de: WO2026120467A1
The present invention relates to the field of medical diagnosis, and more particularly to methods for detecting the risk of having mental health-related diseases by means of analyzing morphological changes in specific immune cells of the central nervous system, such as microglia, using convolutional neural network-based artificial intelligence.
Resumen de: WO2026121369A1
The present invention provides a method for diagnosing neurodegenerative diseases or providing information for the diagnosis thereof in such a manner that magnetic beads to which a first antibody capable of capturing exosomes such as an anti-CD63 antibody is attached is introduced into the blood of a patient to capture exosomes containing neurodegenerative disease-associated proteins, and then a neurodegenerative disease-associated protein-specific antibody is attached to the captured exosomes to perform detection.
Resumen de: US20260160759A1
0000 Provided herein are methods and systems for multiplex detection and/or measurement of biomarkers of a sample. The methods and systems can be used for rapid disease detection and/or monitoring, vaccine efficacy and immune response monitoring, therapeutic drug monitoring, and/or therapeutic safety and efficacy monitoring.
Resumen de: US20260158142A1
Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.
Resumen de: US20260160763A1
0000 This document relates to methods and materials involved in assessing and/or treating mammals having a neurological autoimmune disorder (e.g., a paraneoplastic neurological autoimmune disorder) and/or cancer. For example, methods and materials for detecting anti-neuronal nuclear antibody type 3 (ANNA3) antibodies are provided.
Resumen de: US20260159878A1
0000 Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a cell.
Resumen de: US20260160752A1
0000 A method for co-compartmentalising a cyclic polypeptide with a polynucleotide encoding the cyclic polypeptide, comprising the steps of a) forming a compartment containing a polynucleotide encoding the cyclic polypeptide, b) expressing a polypeptide from the polynucleotide, and c) cyclising the polypeptide. Co-compartmentalised cyclic polypeptides and encoding polynucleotides. Libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Methods for screening libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Incorporation of non-canonical nucleic acids into such libraries.
Resumen de: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Resumen de: JP2026094866A
【課題】破骨細胞障害性疾患および白質脳症を予防または治療する技術を提供する。【解決手段】オプチニューリン（OPTN）関連物質を有効成分として含有する、破骨細胞障害性疾患および白質脳症の予防または治療剤。【選択図】なし
Resumen de: EP4756429A2
0001 The invention relates to novel methods, kits and use of polypeptides for the detection of antibodies against Bovine Herpes Virus Type 1 (BoHV-1) infection in biological samples including milk, pooled milk and bulk milk.
Resumen de: WO2024194609A1
The present invention relates to a method for detecting an analyte in a sample suitable for detecting the analyte over a range of concentrations, the method comprising steps (i)-(v). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region of the optical component in the second optical state. It is the set of local regions of the optical component in the second optical state that are detected.
Resumen de: EP4755889A1
0001 Disclosed are a novel compound for detecting amyloid-beta, and a method of diagnosing a neurodegenerative disease using the same, wherein a compound represented by Formula 1 or a salt thereof according to the present disclosure may specifically bind to amyloid-beta. Due to its high selectivity, the compound or a salt thereof can detect amyloid-beta in plasma with high sensitivity despite interference in detection caused by the presence of other proteins in plasma, and can be utilized for the diagnosis of a neurodegenerative disease or screening for therapeutic agents for a neurodegenerative disease.
Resumen de: CN122163149A
0001 本发明涉及医疗监测与智能预警技术领域，具体是一种多模态融合的CSVD认知功能动态监测与预警系统，解决临床对CSVD患者认知功能与情感障碍的动态、精准、全面监测与预警需求的问题。包括采集获取患者多维数据的多模态数据采集模块；标准化数据的数据预处理模块；提取认知情感特征，构建模型并生成融合特征向量的多模态融合分析模块；实时评估认知功能的认知功能动态监测模块；识别情感状态风险并输出结果的情感状态评估模块、分级预警与建议的风险预警模块、支持数据存储及对接的存储交互模块；可视化呈现监测、评估及预警结果的终端显示模块。本发明通过多模块协同，实现对CSVD患者认知与情感状态的全面监测与精准预警，提升临床应用的针对性和准确性。
Resumen de: WO2024215624A2
This disclosure provides antibodies and methods for preparing and using the same wherein the antibodies bind to PTGFRN on a cell.
Resumen de: WO2024243435A2
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: WO2026115752A1
This urine collection pad (1) comprises a storage member (10) and a holding member (20). The storage member (10) is a member capable of storing urine and has two main surfaces (11) opposite each other. The holding member (20) is a member for holding the storage member (10). The holding member (20) has a poorly permeable layer (22). The poorly permeable layer (22) is a portion having a lower liquid permeability than the storage member (10). The poorly permeable layer (22) covers at least a part of one of the main surfaces of the storage member (10). The storage member (10) is detachable from the poorly permeable layer (22).
Resumen de: CN122150359A
0001 本申请公开了一种三维立体闭合式双极电化学发光侧向流芯片在免疫检测中的应用，所述的芯片包括电极片、试纸条和连接垫；所述的电极片包括两组电极，一组包括阳性驱动电极一、双极电极和阴性驱动电极，另一组是阳性驱动电极二；两组电极分别分布在疏水基底正、反面上；所述阳性驱动电极一与阳性驱动电极二通过导电材料连接。本发明首次将CBPE构建于疏水基底正、反面，形成三维立体CBPE‑ECL电极片，减少了多层电极手动组装所引入的误差，显著提高电极片的一致性与可靠性。
Resumen de: CN122145436A
本发明公开了一种对乙酰胆碱酯酶和黏度双响应的FRET荧光探针及其制备方法和用途，其中FRET荧光探针的结构如下所示：。本发明荧光探针基于荧光共振能量转移（FRET）机制，在短波520 nm响应乙酰胆碱酯酶（AChE），检测限低至0.104 U/L，并在长波680 nm响应黏度，两者波长差高达160 nm，双通道响应无串扰。细胞毒性测试表明该探针的生物相容性良好，共聚焦荧光显微成像实验表明该探针对细胞光稳定性良好，具有双通道同时监测细胞内AChE浓度变化和细胞黏度波动的能力，适用于细胞内AChE浓度变化和黏度波动示踪的共聚焦荧光成像。
Nº publicación: CN122145615A 05/06/2026
Solicitante:
上海宏成药业有限公司
Resumen de: CN122145615A
本发明属于生物医药领域，具体涉及抗LMP1抗体及其应用。本发明的抗体对LMP1具有较好的亲和力和/或生物学活性，可用于检测LMP1、诊断或防治与LMP1相关的疾病或病症。
BOPI
Sede Electrónica
